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A B S T R A C T
Proteinuria is the hallmark of renal disease. In essential hypertension the onset of de novo proteinuria is associated
with faster rate of progression of disase. Some authors have suggested that the DD genotype of the angiotensin-convert-
ing enzyme (ACE) gene would be an adverse renal prognosis factor. It may also have different effects on the reduction of
proteinuria by ACE inhibitors in patients with proteinuria. Observations on the association between the ACE gene poly-
morphism and hypertension have been inconsistent, which might be due to ethnic and geographical variations. In this
study was to investigated the relationship between ACE gene polymorphism and antiproteinuric effect of ACE inhibitors
(ramipril) and to evaluate the possible association between I/D polymorphism and hypertension. We recruited 66 hyper-
tensive patients (male 42, female 24) with overt proteinuria (urinary protein excretion over 500 mg/day). Patients were
classified into three groups in accordance with ACE genotypes (17 DD; 35 ID; 14 II). They were treated with ramipril
and prospectively followed up for one year. Various clinical parameters including age, body mass index (BMI), 24-h urine
protein, creatinine, creatinine clearance (Ccr), systolic and diastolic blood pressure (SBP and DBP), mean arterial pres-
sure (MAP) were measured in the pre- and post-treatment periods. The ACE gene insertion/deletion(I/D) polymorphisms
in intron 16 were determined by PCR. Results showed that there were no significant differences in the clinical parame-
ters such as age, gender, serum creatinine, Ccr, SBP, DBP, MAP, and daily urinary excretion of protein among three
groups (P>0.05). ID genotype patients were found to have lower BMI (p=0.031). ACE inhibition significantly reduced
proteinuria in all genotype groups (p<0.05). The percentage reductions of 24-h urinary excretion of protein were signifi-
cantly different between the genotype groups (p=0.042) and for DD genotype were significantly greater than in ID (79.2±
28.9% vs 49.2±64.8%, P=0.015). The slope of SBP was the main factor related to the slope of the percentage reduction of
proteinuria, however, a significant negative correlation coefficient between these parameters was found (rs=–0.382, p=
0.002). We failed to find significant difference in outcomes of treatments with ACE inhibitor between male and female ac-
cording the I/D polymorphism of the ACE gene. D allele in the ACE genotype could be a useful genetic marker with im-
portant clinical, therapeutic and prognostic implications in recognizing patients with proteinuria that are at greater risk
of renal damage.
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Introduction
Although historically proteinuria has been considered
as a simply a surrogate marker of the severity of underly-
ing glomerular damage, clinical and experimental data
reported during more than a decade of intensive investi-
gation indicate that proteinuria is an independent risk
factor and plays an important role in the pathogenesis of
the progression of renal disease1–3.
Recent evidence suggests that proteinuria can direct-
ly cause renal damage through lysosomal injury, growth
factor induced tubular fibrosis and transcriptase genes
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which trigger vasoactive and inflammatory renal dama-
ge1–6.
The renin angiotensin system which releases angio-
tensin II, a most powerful vasoconstrictor and mediator
of mesangial cell proliferation and matrix expansion, has
been associated with progressive renal injury.
Angiotensin II, a central component of renin-angio-
tensin system (RAS), acts as a strong promoter that dra-
matically potentiates the ability of transforming growth
factor â (TGF-â) to induce epithelial to mesenchimal tran-
sition (EMT) in tubular epithelial cells7.
The relationship between proteinuria and poor prog-
nosis in renal disease, as well as the link between reno-
protection and protein traffic reduction by ACE inhibitors
have been firmly established8,9. However, the antipro-
teinuric effect of ACE inhibitors on proteinuria is vari-
able and the percentage of reducing proteinuria is in the
range of 20–80% in a variety of renal disease and may be
related to the type of the patient´s ACE genotype10.
The ACE gen is located on the log arm of chromosome
17. Insertion or deletion of any of the 287 base pair frag-
ments in the 16th intron of the ACE gene may determine
its genotype.
These genotypes are used to characterize the poly-
morphism as DD, ID and II type11.
It has been reported that each of these genotypes
appeared to be a major determinant of plasma and tissue
activities. Individuals with DD genotype have the great-
est and those with II genotype the least ACE concentra-
tions11–13. However, because the ACE I/D polymorphism
is intronic, the mechanism of ACE overexpression in
subjects with DD genotype is unclear; it is possible that
this relationship is the result of tight linkage to another
locus involved in the regulation of ACE gene expres-
sion14.
Observations on the association between ACE poly-
morphism and essential hypertension have been incon-
sistent, which might be due to ethnic and geographical
variations. No correlation has been found between plas-
ma ACE levels and hypertension or between ACE DD ge-
notype and hypertension15–16. A study of Zee et al.17
showed a positive association between ACE polymor-
phism and hypertension, with a higher frequency of the I
allele in hypertensive patients with a family history of
hypertension, compared to normotensive controls.
Numerous studies have addressed the role of RAS
gene polymorphisms in the development and progression
of renal disease18–27. There is increasing evidence that
the progression of diabetic nephropathy is more rapid in
patients with DD genotype. Yoshida et al.19 for example,
report an OR for loss of renal function in diabetics with a
DD genotype of 3.42 and consider ACE polymorphism to
be a genetic marker for the progression to chronic renal
failure in diabetics. They also showed a similar associa-
tion in IgA nephropathy20. Administration of ACE inhibi-
tors has been shown to lead to a significant decrease of
proteinuria in chronic renal diseases, including nondia-
betic renal diseases. The ACE genotype appears to pre-
dict the therapeutic efficacy of ACE inhibition of protein-
uria; II genotype patients are resistant to this renopro-
tective therapy, whereas DD genotype patients have a
significant reduction in the degree of proteinuria19,20,25–28.
However there are also contradictory observation21–24.
There is still no consensus on using ACE genotyping in
the setting of diabetic and nondiabetic nephropathy, be-
cause reported studies to date are on limited size patient
groups, and large prospective studies would be necessary
to assess the impact of the ACE polymorphism on the re-
sponse to renoprotective treatment.
In the present study we investigated the antipro-
teinuric effect of ACE inhibitors (ramipril) in relation to
ACE I/D polymorphism and evaluated the possible asso-
ciation between I/D polymorphism and hypertension in
an observational one year follow-up study of patients
with overt proteinuria and hypertension.
Patients and Methods
Sixty-six patients with overt proteinuria (mean value
of the urinary protein excretion over 500 mg/day in the
baseline status) were recruited from the Department of
Nephrology, Dubrava University Hospital, Zagreb, Croa-
tia from 2007 to 2009. They were classified into three
groups in accordance with their ACE genotypes (17 DD;
35 ID; 14 II). They were prospectively followed up for 12
months. Before enrollment in the study, all the patients
signed informed consent forms. Previosly used ACE in-
hibitors were withdrawn for at least one month, non-ste-
roidal antiinflammatory drugs, corticosteroids or immu-
nosuppressive drugs for et least six months before the
study. Baseline proteinuria were measured using a 24-h
urine collections. The mean values of the to measure-
ments were taken as the baseline data. Blood pressure
was measured following ESH/ECS guidlines using mer-
cury sphyngomanometer. Mean arterial pressure (MAP)
was calculated as the sum of two-thirds of the diastolic
and one-third of the systolic blood pressure. A diagnosis
of hypertension was made if the patient had two consecu-
tive blood pressure readings >140/90 or if MAP was
above 105 mmHg. Various clinical parameters including
age, gender, body mass index (BMI), 24-h urinary excre-
tion of sodium and protein, serum creatinine, creatinine
clearance (Ccr) and MAP were measured in the pre- and
post-treatment period (12 months) with standard labora-
tory techniques. During the one year study period pa-
tients were treated with ramipril (5 mg/day). The dose
was doubled if blood pressure after 1 month was ³140/90
mmHg. If the blood presure after 3 months was still ³
140/90 mmHg, another antihypertensive drug was added
(indapamidum, calcium channel blockers, beta-blockers,
furosemid). Dietary intake for sodium and patient medi-
cation were not changed during the study period. All pa-
tients with normal coagulation factors, whose ultrasound
kidney size was greater than 9 cm and the thickness of
renal parenchyma greater than 10 mm, after a good con-
trol of blood pressure underwent percutaneous renal bi-
opsy. The main indications for renal biopsy were nephro-
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tic syndrome, hematuria and/or non-nephrotic protein-
uria and renal failure. Biopsy was done using continuous
ultrasound guidance and a 16-gauge biopsy needle (Tru-
-Cut) in an automated gun (Biopty Bard, USA). All biop-
sies were processed for light, immunofluorescence and
electron microscopy.
Genotyping of ACE I/D polymorphism
For determination of I/D polymorphism of ACE gene,
genomic DNA was extracted from peripheral blood leu-
kocytes. A 287-bp I/D polymorphism in the intron 16 of
the ACE gene was examined by polymerase chain reac-
tion (PCR). PCR was performed according to the method
of Fernandez-Llama et al.29 The sequence of the sense
and the antisense primers were 5´-CTGGAGACCACT
CCCATCCTTTCT-3´ and
5´-GATGTGGCCATCACATTCGTCAGAT-3’ respec-
tively. PCR was performed in a final volume of 25 mL that
contained 200 ng of genomic DNA, 1.0 mm of each primer,
1.5 mmol/L MgCl2, 50 mmol/L KCl, 0.25 mmol/L dNTP,
10 mmol/L Tris-HCl (PH 8.4), and 1 U Taq DNA poly-
merase. Amplification was carried out for 35 cycles with
steps of denaturation at 94 °C for 2 min, annealing at
58 °C for 15 s, and extension at 72 °C for 30 s. The PCR
products were subjected to electrophoresis in 1.5% aga-
rose gels and stained by ethidium bromide for visualiza-
tion. To avoid mistyping of the ID genotype as DD, we
confirmed the accuracy of the genotyping results using
an insertion-specific primer pair (5’-TGG GAC CAC AGC
GCC CGC CAC TAC-3’ i 5’-TCG CCA GCC CTC CCA
TGC CCA TAA-3’) according to the method of Shan-
mugam et al.30
Statistical analysis
All data are presented as X±SD except urinary pro-
tein. A one-way ANOVA test was used to analyse bet-
ween group and within group differences. A paired Stu-
dent´s t-test was used to test for differences between the
baseline values and those after ACE inhibition therapy.
Variables with skewed distribution (e.g. creatinine) were
logarithmically transformed and then tested by Stu-
dent´s t-test. The non-parametric Mann-Whitney U test
were used to analyze variable with skewed distributions
in spite of logarithmic transformations (e.g. urinary pro-
tein excretion). Differences in frequency were determi-
ned by c2 analysis with the Yates correction. The correla-
tion analysis was performed and the correlation coeffi-
cients were calculated. Simple linear regression analysis
was applied when appropriate. Statistical significance
was assumed at a 5% level. Statistical analysis was per-
formed using SPSS 15.0 for Windows, computer soft-
ware.
Results
The 66 participants included 42 men (63.6%) and 24
(36.4%) women. The frequency of ACE genotypes was
26%:53%:21%, respectively D allele frequency was 79%.
The distribution of ACE genotypes observed were in
agreement with the Hardy-Weinberg proportion and
were consistent with other published reports.
Clinical and biochemical baseline characteristics of
patients before initiating ACE inhibitors are shown in
Table 1. There were no significant differences in the clin-
ical parameters such as age, gender, systolic (SBP) and
diastolic blood pressure (DBP), MAP, serum creatinine
and creatinine clearance (Ccr) among three groups
(p>0.005, Table 1). However, the median values of base-
line daily urinary excretion of protein for DD genotype
was greater than that of ID and II genotypes but statisti-
cally nonsignificant. ID genotype patients were found to
have lower BMI (p=0.031). The majority of patients had
glomerulonephritis (GN): focal segmental glomeruoscle-
rosis (FSGS) in 27%, membranous GN in 21%, IgA
nephropathy in 19.7%, crescentic GN in 3%, minimal
change disease (MCD) in 1.5%, lupus nephritis in 3% and
chronic GN in 6% cases. Tubulointerstitial nephritis was
found in 3% cases, vascular disease and diabetic nephro-
pathy in 3% case and nephroangiosclerosis in 6% case.
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TABLE 1
CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF PATIENTS WITH OVERT PROTEINURIA BY ACE GENOTYPES BEFORE
TREATMENT WITH ACE INHIBITORS
Variables DD ID II
No. of patients (M:F) 17 (13:4) 35 (20:15) 14(9:5)
Age (years) 50.6±14.2 43.1±16.6 53.0±14.8
BMI (kg/m2) 28.4±5.1 25.7±4.4* 28.9±3.8
Creatinine (mmol/L)a 101.0 (72–598) 105.0 (61–404) 125.5 (56–265)
Creatinine clearance (mL/min/1.73 m2) 76.4±27.1 71.8±28.4 76.0±37.7
24-h urinary protein excretion (g/day)a 4.8 (1.0–23.1) 4.4 (0.5–22.8) 5.6 (1.2–16.2)
Systolic blood pressure (mmHg) 140.2±26.1 133.9±20.9 138.9±19.2
Diastolic blood pressure (mmHg) 89.9±13.2 84.3±13.4 89.6±10.6
Mean arterial pressure (mmHg) 106.7±16.3 100.8±15.3 105.2±14.3
All data are expressed as X±SD except creatinine and urine protein, amedian (minimum-maximum), BMI – body mass index,
ACE – angiotensin-converting enzyme, *p<0.05, as compared to DD and II genotypes by one-way ANOVA test.
After the 12-month treatment using ACE inhibitor
(ramipril), there were no significant differences in the re-
duction of blod pressure and creatinine clearance among
three groups (p>0.005, Table 2).
One year of ACE inhibition resulted in significant re-
duction of proteinuria in all three genotype groups. The
magnitude of the responses varied between individuals.
Comparison of proteinuria before and after treatment
with ACE inhibitors in the three different genotypes are
shown in Figure 1.
There were no statistically significant differences bet-
ween values of protein excretion after ACE inhibition
among the three groups (p>0.05, Table 2).
The percentage reductions of 24-h urinary excretion
of protein were significantly different between the geno-
type groups (p=0.042) and for DD genotype were signifi-
cantly greater than in ID (79.2±28.9% vs 49.2±64.8%,
p=0.015). (Table 2, Figure 2). There was no statistically
significant correlation between the levels of baseline
proteinuria and the percentage reduction of proteinuria
after ACE inhibition (r=0.143, p=0.252).
The slope of SBP was the main factor related to the
slope of the percentage reduction of proteinuria, how-
ever, a significant negative correlation coefficient bet-
ween these parameters was found (rs=–0.382, p=0.002,
Figure 3). To examine the sex-specific association of the
ACE genotype in hypertensive patients with overt pro-
teinuria we compared outcomes of treatments with ACE
inhibitors according the I/D polymorphism of the ACE
gene separately among men and women. However, the
percentage reduction of proteinuria after treatment with
ACE inhibitor for D allele was greater and equally in
men and women than for I allele, statistically was not
significant. We failed to find significant difference in out-
comes of treatments with ACE inhibitor between male
and female.
Discussion
In the present study, we evaluated whether the effect
of ACE inhibition on proteinuria, blood pressure and re-
nal haemodynamics were affected by the ACE genotypes
in hypertensive patients with overt proteinuria. We
found that patients with DD genotype are more suscepti-
ble to the antiproteinuric effect of ACE inhibition than
those with ID or II.
Many of the previous association studies that focused
on the association between ACE gene polymorphism and
the development and progression of renal disease yielded
conflicting results. In the study of Yoshida et al.20 that in-
cluded 53 Japanese patients with biopsy-proven IgA
nephropathy, proteinuria was significantly decreased af-
ter ACE inhibitor administration in patients with DD
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TABLE 2
COMPARISON OF CLINICAL FINDINGS AMONG THE THREE GENOTYPES AFTER TREATMENT WITH ACE INHIBITORS
Variables DD ID II
Creatinine (mmol/L)a 152 (72–679) 100 (52–656) 115 (56–284)
Creatinine clearance (mL/min/1.73 m2) 81.6±39.4 90.9±45.5 78.3±48.9
24-h urinary protein excretion (g/day)a 0.5 (0–6) 1.0 (0–26) 1.1 (0–11)
Systolic blood pressure (mmHg) 141.8±19.7 141.3±18.1 136.3±14.1
Diastolic blood pressure (mmHg) 89.4±10.1 86.4±10.3 85.4±9.3
Mean arterial pressure (mmHg) 106.9±11.8 104.7±11.9 102.3±9.9
Proteinuria reduction rate (%) 79.2±28.9* 49.2±64.8 50.7±42.9
Ccr reduction (mL/min/1.73 m2) 5.2±46.0 19.0±34.1 2.3±32.3
All data are expressed as X±SD except creatinine and urine protein, amedian (minimum-maximum), Ccr – creatinine clearance,
ACE – angiotensin-converting enzyme, *p<0.05, as compared to ID and II genotypes by one-way ANOVA test.
Fig. 2. Percentage reduction of proteinuria according to ACE ge-
notype before and after treatment of ACE inhibitor. *p<0.05,
compared to ID and II genotypes by one-way ANOVA test.
Fig. 1. Comparison of proteinuria before and after treatment
with ACE inhibitors in the three genotypes. *p<0.05 by Wilcoxon
paired test (ACE inhibitors vs baseline). Median values are indi-
cated by the horizontal lines.
genotype but not in those with ID or II. The study of
Sung-Kyu Ha et al.26 also showed that the ACE DD geno-
type may have a significant role in the antiproteinuric ef-
fect of the ACE inhibitors. REIN trial28 reported that
polymorphism of ACE gene is a strong predictor of ACE
inhibition-associated renoprotection., progression to
ESRD and proteinuria were effectively reduced in pa-
tients with DD but not in those with ID or II genotype.
Moriyama et al.10 found better antiproteinuric res-
ponse to ACE inhibition in patients with II genotype in
the study included 36 patients with various renal disor-
der. Penno et al.22 reported from the EUCLID trial signif-
icant beneficial antiproteinuric effect of the ACE inhibi-
tors also in patients with II genotype. Jacobsen at al.21
concluded that hypertensive albuminuric patients with
II genotype were particularly susceptible to renoprotec-
tive therapy. Our present observation does not coincide
with EUCLID, Moriyama and Jacobsen studies, but con-
curs with many others19,20,25–28. The antiproteinuric ef-
fect of the ACE inhibitors has been thought to be inde-
pendent of its antihypertensive effect on the systemic
blood pressure. In this study we did not find any signifi-
cant differences in SBP, DBP and MAP fall among the
three genotype groups and our observation coincide with
other reports15,26,34. However, the antiproteinuric effect
of ACE inhibition in DD genotype was pronounced com-
pared to II or ID genotypes.To exclude possibility that
antiproteinuric effect of ACE inhibitors could be affected
by sodium intake, during the study period dietary so-
dium intake was not changed and sodium excretion was
similar among three groups.
There was no statistically significant correlation bet-
ween the levels of baseline proteinuria and the percent-
age reduction of proteinuria after ACE inhibition (r=
0.143, p=0.252). These findings suggest that the amount
of baseline proteinuria do not affect the magnitude of the
percentage reduction of proteinuria after ACE inhibi-
tion.
The slope of SBP was the main factor related to the
slope of the percentage reduction of proteinuria, how-
ever, a significant negative correlation coefficient bet-
ween these parameters was found (rs=–0.382, p=0.002).
Gender has been reported to have an impact on the
development and progression of renal insufficiency31, in-
dicated that men with chronic renal disease of various
etiologies show a more rapid decline in renal function
with time than in women32. It has been speculated that
direct receptor-mediated effects of sex hormones may de-
termine susceptibility to renal damage33. Samuelsson et
al.25 reported that DD genotype was a significant predic-
tor of a more rapid decline in renal function in male, but
not female, patients while Ruggenenti et al.27 found that
ramipril uniformly decreased DGFR and incidence of
ESRD in women either DD or II+ID genotype and in
men with DD genotype but had no beneficiall effect in
men with the II+ID genotype.
In the present study, the subgroup analysis of the al-
lele distributions between males and females and analy-
sis of gender-dependent interactions between the ACE
gene and outcomes of treatments with ACE inhibitors
failed to show any significance. Our observations may
have been due to the small sample size of the female pa-
tient group compared to the male group.
In conclusion, the results of the present study show
that the antiproteinuric effect of ACE inhibitors in DD
genotype is significantly higher than that in ID or II ge-
notypes.
As to the distribution of allele D and I, allele D is more
frequent than allele I. This result corresponds with pre-
vious reports, suggesting an ethnic differences35,36. D al-
lele in the ACE genotype could be a useful genetic
marker with important clinical, therapeutic and prog-
nostic implications in recognizing patients with protein-
uria that are at greater risk of renal damage.
Although our study is limited by sample size, large
prospective studies would be necessary to assess the im-
pact of the ACE polymorphism on the response to
renoprotective treatment.
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UTJECAJ POLIMORFIZMA GENA ANGIOTENZIN I KONVERTAZE (ACE) NA PROTEINURIJU
I ARTERIJSKU HIPERTENZIJU
S A @ E T A K
Proteinurija je najraniji znak o{te}enja bubrega. U esencijalnoj hipertenziji pojava proteinurije povezana je s br`om
progresijom bolesti. Neki autori su predlo`ili da bi DD genotip angiotenzin I konvertaze mogao biti nepovoljan ~im-
benik prognoze u bubre`nih bolesti, ali i utjecati na u~inke lije~enja s ACE inhibitorima u bolesnika s proteinurijom.
Rezultati dosada{njih zapa`anja o povezanosti polimorfizma ACE gena i arterijske hipertenzije ~esto su opre~ne i ne-
konzistentne, vjerojatno i zbog etni~kih i geografskih varijacije. Cilj ove studije bio je ispitati utjecaj I/D polimorfizma
ACE gena na ishod lije~enja bolesnika s proteinurijom i povi{enim krvnim tlakom s ACE inhibitorom (ramiprilom). U
studiju je uklju~eno 66 bolesnika s proteinurijom (izlu~ivanje proteina urinom vi{e od 500 mg dnevno) i arterijskom
hipertenzijom. Bolesnici su bili podijeljeni u tri grupe prema ACE-genotipu (17 DD, 35 ID, 14 II) te lije~eni ramiprilom i
prospektivno pra}eni godinu dana. Razli~iti klini~ki parametri uklju~uju}i dob, indeks tjelesne mase (IM), 24-h protein-
uriju, kreatinin u serumu, klirens kreatinina (Ccr), sistoli~ki i dijastoli~ki krvni tlak (SKT i DKT), srednji arterijski
tlak, izmjereni su prije i nakon lije~enja. Insercijsko/delecijski polimorfizam ACE gena unutar introna 16 odre|en je
metodom PCR. Rezultati su pokazali da nije bilo zna~ajne razlike me|u genotipovima u klini~kim parametrima kao {to
su spol, dob, kreatinin, Ccr, SKT, DKT, 24-satna proteinurija (p>0,05). Bolesnici s ID genotipom imali su ni`i ITM
(p=0,031). ACE inhibicija zna~ajano smanjuje proteinuriju u svim skupinama (p<0,05). Utvr|ena je statisti~ki zna-
~ajna razlika u postotku smanjenja proteinurije me|u genotipovima (p=0,042); za DD genotip bio je statisti~ki zna~ajno
ve}i nego u ID (79,2±28,9% vs. 49,2±64,8%, p=0,015). Reductions in systolic and diastolic blood pressure did not differ
significantly among genotypes.There was significant negative correlation between systolic blood pressure and percent-
age reductions of proteinuria (rs=–0,382; p=0,002).Na|ena je statisti~ki zna~ajna negativna korelacija izme|u sisto-
li~kog krvnog tlaka i postotka smanjenja proteinurije (rs=– 0,382, p=0,002). Nismo uspjeli prona}i zna~ajne razlike u
ishodima lije~enja s ACE inhibitorom izme|u mu{karaca i `ena s obzirom na I/D polimorfizam ACE gena. D alel mogao
bi biti koristan genski biljeg sa va`nim klini~kim, terapeutskim i prognosti~kim implikacijama u prepoznavanju boles-
nika s proteinurijom koji imaju ve}i rizik za bubre`no o{te}enje.
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